



## Clinical trial results:

### An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed with or without Cixutumumab as First-Line Therapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Carcinoma

#### Summary

EudraCT number	2010-024014-60
Trial protocol	DE IT BE
Global end of trial date	10 June 2016

#### Results information

Result version number	v1 (current)
This version publication date	25 June 2017
First version publication date	25 June 2017

#### Trial information

##### Trial identification

Sponsor protocol code	I5A-MC-JAEM
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01232452
WHO universal trial number (UTN)	-
Other trial identifiers	Trial ID: 13973

Notes:

#### Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri, 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-285-4559,
Scientific contact	Available Mon - Fri, 9 AM - 5 PM EST, Eli Lilly and Company, 1 877-CTLilly,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 June 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	10 June 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma (NSCLC) as measured by progression-free survival (PFS).

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 April 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	1 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 5
Country: Number of subjects enrolled	Belgium: 13
Country: Number of subjects enrolled	France: 5
Country: Number of subjects enrolled	Germany: 25
Country: Number of subjects enrolled	Italy: 19
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	Argentina: 13
Country: Number of subjects enrolled	Brazil: 36
Country: Number of subjects enrolled	Turkey: 12
Country: Number of subjects enrolled	United States: 21
Country: Number of subjects enrolled	Israel: 8
Country: Number of subjects enrolled	Spain: 13
Worldwide total number of subjects	172
EEA total number of subjects	80

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	126
From 65 to 84 years	46
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

No Text Entered

### Pre-assignment

Screening details:

Completers are those participants who died or had progressive disease (PD).

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Pemetrexed + Cisplatin + Cixutumumab
------------------	--------------------------------------

Arm description:

Induction Treatment: Pemetrexed 500 mg/m<sup>2</sup> plus cisplatin 75 mg/m<sup>2</sup> plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for participants with significant tumor size reduction, after sponsor approval.

Maintenance Therapy: Pemetrexed 500 mg/m<sup>2</sup> plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.

Arm type	Experimental
Investigational medicinal product name	pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pemetrexed 500 mg/m<sup>2</sup> was given IV on Day 1 of a 21 day cycle for up to 4 cycles.

Investigational medicinal product name	cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

cisplatin 75 mg/m<sup>2</sup> was given IV on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for participants with significant tumor size reduction, after sponsor approval.

Investigational medicinal product name	cixutumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

20 mg/kg given IV on Day 1 of a 21 day cycle for up to 4 cycles.

<b>Arm title</b>	Pemetrexed + Cisplatin
------------------	------------------------

Arm description:

Induction Treatment: Pemetrexed 500 mg/m<sup>2</sup> plus cisplatin 75 mg/m<sup>2</sup> given IV on Day 1 of a 21 day

cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for participants with significant tumor size reduction, after sponsor approval.

Maintenance Therapy: Pemetrexed 500 mg/m<sup>2</sup> given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.

Arm type	Active comparator
Investigational medicinal product name	pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pemetrexed 500 mg/m<sup>2</sup> was given IV on Day 1 of a 21 day cycle for up to 4 cycles.

Investigational medicinal product name	cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Cisplatin 75 mg/m<sup>2</sup> was given IV on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for participants with significant tumor size reduction, after sponsor approval.

Number of subjects in period 1	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin
Started	87	85
Received at least one dose of study drug	85	81
Completed	48	46
Not completed	39	39
Consent withdrawn by subject	11	8
Physician decision	8	12
Adverse event, non-fatal	17	15
Sponsor Decision	3	1
Protocol entry criterion not met	-	1
Protocol deviation	-	2

## Baseline characteristics

### Reporting groups

Reporting group title	Pemetrexed + Cisplatin + Cixutumumab
-----------------------	--------------------------------------

Reporting group description:

Induction Treatment: Pemetrexed 500 mg/m<sup>2</sup> plus cisplatin 75 mg/m<sup>2</sup> plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for participants with significant tumor size reduction, after sponsor approval.

Maintenance Therapy: Pemetrexed 500 mg/m<sup>2</sup> plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.

Reporting group title	Pemetrexed + Cisplatin
-----------------------	------------------------

Reporting group description:

Induction Treatment: Pemetrexed 500 mg/m<sup>2</sup> plus cisplatin 75 mg/m<sup>2</sup> given IV on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for participants with significant tumor size reduction, after sponsor approval.

Maintenance Therapy: Pemetrexed 500 mg/m<sup>2</sup> given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.

Reporting group values	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin	Total
Number of subjects	87	85	172
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: years			
arithmetic mean	59.5	59.3	
standard deviation	± 9.87	± 9.96	-
Gender categorical			
Units: Subjects			
Female	33	32	65
Male	54	53	107
Race			
Units: Subjects			
American Indian or Alaska Native	0	1	1
Asian	1	0	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	2	3
White	81	80	161

More than one race	0	0	0
Unknown or Not Reported	4	2	6
Ethnicity			
Units: Subjects			
Hispanic or Latino	13	24	37
Not Hispanic or Latino	45	33	78
Unknown or Not Reported	29	28	57

## End points

### End points reporting groups

Reporting group title	Pemetrexed + Cisplatin + Cixutumumab
-----------------------	--------------------------------------

Reporting group description:

Induction Treatment: Pemetrexed 500 mg/m<sup>2</sup> plus cisplatin 75 mg/m<sup>2</sup> plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for participants with significant tumor size reduction, after sponsor approval.

Maintenance Therapy: Pemetrexed 500 mg/m<sup>2</sup> plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.

Reporting group title	Pemetrexed + Cisplatin
-----------------------	------------------------

Reporting group description:

Induction Treatment: Pemetrexed 500 mg/m<sup>2</sup> plus cisplatin 75 mg/m<sup>2</sup> given IV on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for participants with significant tumor size reduction, after sponsor approval.

Maintenance Therapy: Pemetrexed 500 mg/m<sup>2</sup> given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.

### Primary: Progression-free Survival (PFS)

End point title	Progression-free Survival (PFS)
-----------------	---------------------------------

End point description:

PFS was defined as the time from date of randomization until the date of disease progression, or death from any cause, whichever was first. Disease progression was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, and/or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions. Participants without documentation for disease progression or death were censored at the date of last tumor assessment. The PFS was estimated following the Kaplan-Meier method.

End point type	Primary
----------------	---------

End point timeframe:

Randomization Date to Disease Progression or Death From Any Cause Up to 18.3 Months

End point values	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[1]</sup>	85 <sup>[2]</sup>		
Units: months				
median (confidence interval 95%)	5.45 (3.88 to 6.05)	5.22 (4.24 to 6.74)		

Notes:

[1] - All randomized participants. 20 participants censored.

[2] - All randomized participants. 21 participants censored.

### Statistical analyses



<b>Statistical analysis title</b>	Statistical Analysis for PFS
Comparison groups	Pemetrexed + Cisplatin + Cixutumumab v Pemetrexed + Cisplatin
Number of subjects included in analysis	172
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.848
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.47

### Secondary: Percentage of Participants Achieving an Objective Response Rate (ORR)

End point title	Percentage of Participants Achieving an Objective Response Rate (ORR)
End point description:	
<p>The ORR is the percentage of all participants with Partial Response (PR) or Complete Response (CR) according to RECIST v1.1. Disease progression was defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, and/or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions. ORR is confirmed best overall tumor response of CR and PR. CR was defined as the disappearance of all target and non-target lesions; PR defined as a &gt;30% decrease in the sum of the longest diameters (LD) of the target lesions, taking as reference the baseline sum of the LD.</p>	
End point type	Secondary
End point timeframe:	
Randomization Date to Disease Progression Up to 18.3 Months	

End point values	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[3]</sup>	85 <sup>[4]</sup>		
Units: percentage of participants				
number (confidence interval 95%)	37.9 (27.7 to 49)	30.6 (21 to 41.5)		

Notes:

[3] - All randomized participants.

[4] - All randomized participants.

### Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis for ORR
Comparison groups	Pemetrexed + Cisplatin v Pemetrexed + Cisplatin + Cixutumumab

Number of subjects included in analysis	172
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.338
Method	Fisher exact

### Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description:	
Overall survival is defined as the time from the date of randomization to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive. OS was estimated using the Kaplan-Meier method.	
End point type	Secondary
End point timeframe:	
Randomization Date to Death From Any Cause Up to 20 Months	

End point values	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[5]</sup>	85 <sup>[6]</sup>		
Units: months				
median (confidence interval 95%)	10.68 (8.74 to 9999)	10.38 (7.43 to 14.39)		

Notes:

[5] - Upper limit was not estimable due to data had insufficient events. 47 participants censored.

[6] - All randomized participants. 39 participants censored.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR)
End point description:	
DOR is measured by the time measurement criteria are first met for CR/PR until the first date that the criteria for PD is met, or death is objectively documented. DOR was estimated using the Kaplan-Meier method. Disease progression was assessed via RECIST version 1.1, and defined as at least a 20% increase in the sum of the longest recorded since the baseline measurements, and/or the appearance of one or more new lesion(s), and/or unequivocal progression of existing non-target lesions.	
End point type	Secondary
End point timeframe:	
Time from Response to Disease Progression or Death from Any Cause Up to 20 Months	

End point values	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	23 <sup>[7]</sup>	18 <sup>[8]</sup>		
Units: months				
median (confidence interval 95%)	4.9 (4.17 to 6.28)	3.91 (2.92 to 6.41)		

Notes:

[7] - All randomized participants. 10 participants censored.

[8] - All randomized participants. 8 participants censored.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Progressive Disease (TTPS)

End point title	Time to Progressive Disease (TTPS)
-----------------	------------------------------------

End point description:

TTPS was defined as the time from the date of randomization until the date of disease progression. Disease progression was assessed via RECIST version 1.1, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, and/or the appearance of one or more new lesion(s), and/or unequivocal progression of existing non-target lesions. TTPS was estimated using the Kaplan-Meier method.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization Date to disease progression Up to 18.3 Months

End point values	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[9]</sup>	85 <sup>[10]</sup>		
Units: months				
median (confidence interval 95%)	6.05 (5.32 to 7.79)	6.05 (4.93 to 7.89)		

Notes:

[9] - All randomized participants. 39 participants censored.

[10] - All randomized participants. 36 participants censored.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Worsening of Symptoms as Measured by Lung Cancer Symptom Scale (LCSS) Score

End point title	Time to Worsening of Symptoms as Measured by Lung Cancer Symptom Scale (LCSS) Score
-----------------	---

End point description:

TTPS was defined as the time from the date of randomization until the date of worsening of symptoms as measured by Lung Cancer Symptom Scale (LCSS) score. Symptomatic progression was defined as an increase (worsening) of the Average Symptomatic Burden Index (ASBI) that is, the mean of the six major lung cancer specific symptom scores of the LCSS patient scale - ranging from 0 to 100 where

higher score indicates worst outcome). For each participant, the maximum improvement over baseline score was calculated for each of the 9 LCSS items, ASBI and LCSS total score. Participants without event are censored at the date of the last LCSS assessment. TTPS was estimated using the Kaplan-Meier method.

End point type	Secondary
End point timeframe:	
Time to worsening of symptoms as measured by LCSS score Up to 18.3 Months	

End point values	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[11]</sup>	85 <sup>[12]</sup>		
Units: months				
median (confidence interval 95%)	2.14 (1.54 to 2.99)	4.21 (2.43 to 5.36)		

Notes:

[11] - All randomized participants. 38 participants censored.

[12] - All randomized participants. 46 participants censored.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants With a Change in Tumor Size (CTS)

End point title	Percentage of Participants With a Change in Tumor Size (CTS)
End point description:	
CTS was measured by percentage change of tumor size at the end of Cycle 2 comparing to baseline tumor size.	
End point type	Secondary
End point timeframe:	
Change from baseline measurement to the end of Cycle 2	

End point values	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[13]</sup>	85 <sup>[14]</sup>		
Units: Percentage of Participants				
arithmetic mean (standard deviation)	-23.88 (± 18.859)	-16.04 (± 26.143)		

Notes:

[13] - All randomized participants.

[14] - All randomized participants.

### Statistical analyses

No statistical analyses for this end point

**Secondary: Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Cixutumumab, Cycle 1 (First Infusion) and Cycle 4 (Fourth Infusion)**

End point title	Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Cixutumumab, Cycle 1 (First Infusion) and Cycle 4 (Fourth Infusion) <sup>[15]</sup>
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

First Infusion: [Prior to Infusion (of Cycle1): 1, 72, 168, 336 hours(hrs) and 504 hrs (i.e. Prior to Infusion of Cycle 2)] and Fourth Infusion; [Prior to Infusion (of Cycle 4), 1, 24, 72, 120, 168, 240, 336 hrs and 504 hrs (i.e. Prior to Infusion of Cycle 5)]

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The secondary objective is to assess PK profile of pemetrexed + cisplatin + cixutumumab arm only.

<b>End point values</b>	Pemetrexed + Cisplatin + Cixutumumab			
Subject group type	Reporting group			
Number of subjects analysed	71 <sup>[16]</sup>			
Units: microgram/milliliter (ug/mL)				
geometric mean (geometric coefficient of variation)				
First Infusion (n=71)	481 (± 33)			
Fourth Infusion (n=31)	556 (± 17)			

Notes:

[16] - Participants were randomized to pemetrexed + cisplatin + cixutumumab arm and had evaluable PK data.

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Pharmacodynamics (PD) Markers: Free Insulin-like Growth Factor-I (IGF-I, Total IGF-I, and IGF Binding Proteins (IGFBP-3))**

End point title	Pharmacodynamics (PD) Markers: Free Insulin-like Growth Factor-I (IGF-I, Total IGF-I, and IGF Binding Proteins (IGFBP-3)) <sup>[17]</sup>
-----------------	---

End point description:

Blood samples for the determination of PD marker concentrations were collected at the specified time points for all participants. Analysis of the following markers include free IGF-I, total IGF-I, and IGFBP-3.

End point type	Secondary
----------------	-----------

End point timeframe:

Preinfusion, Cycle 2, Cycle 4, Cycle 8, Postinfusion, 30-Day Follow-Up

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The secondary objective is to assess the PD profile of pemetrexed + cisplatin + cixutumumab arm only.

<b>End point values</b>	Pemetrexed + Cisplatin + Cixutumumab			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[18]</sup>			
Units: Number of Participants				

Notes:

[18] - Zero participants were analyzed due to blood samples were not collected to assess biomarker data.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Immunogenicity of Cixutumumab

End point title	Immunogenicity of Cixutumumab <sup>[19]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Preinfusion, Cycle1(C1): 1, 72, 168, 240, 336 hours(hrs); C2 and C3: 1, 168, 336 hrs; C4: 1, 24,72,120,168, 240, 336, 504 hrs, Postinfusion; 30 Day Follow Up

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The secondary objective is to assess the immunogenicity of pemetrexed + cisplatin + cixutumumab arm only.

<b>End point values</b>	Pemetrexed + Cisplatin + Cixutumumab			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[20]</sup>			
Units: Number of Participants				

Notes:

[20] - Zero participants were analyzed due to no immunogenicity analysis was done and assay never developed

## Statistical analyses

No statistical analyses for this end point

## Secondary: PK: Area Under the Concentration Time Curve (AUC[0-inf]) of Cixutumumab, Cycle 1 (i.e. First Infusion)

End point title	PK: Area Under the Concentration Time Curve (AUC[0-inf]) of Cixutumumab, Cycle 1 (i.e. First Infusion) <sup>[21]</sup>
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to Infusion (of Cycle 1), 1, 72, 168, 336 hrs and 504 hrs (i.e. Prior to Infusion of Cycle 2)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The secondary objective is to assess the PK profile of pemetrexed + cisplatin + cixutumumab arm only.

End point values	Pemetrexed + Cisplatin + Cixutumumab			
Subject group type	Reporting group			
Number of subjects analysed	57 <sup>[22]</sup>			
Units: microgram*hour/milliliter (ug*hr/mL)				
geometric mean (geometric coefficient of variation)	73200 ( $\pm$ 35)			

Notes:

[22] - Participants were randomized to pemetrexed + cisplatin + cixutumumab arm and had evaluable PK data.

### Statistical analyses

No statistical analyses for this end point

### Secondary: PK: Area Under the Concentration Time Curve During 1 Dosing Interval (i.e. 504 hr, AUC(0-tau) of Cixutumumab, Cycle 4 (i.e. Fourth Infusion)

End point title	PK: Area Under the Concentration Time Curve During 1 Dosing Interval (i.e. 504 hr, AUC(0-tau) of Cixutumumab, Cycle 4 (i.e. Fourth Infusion) <sup>[23]</sup>
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Prior to Infusion (of Cycle 4), 1, 24, 72, 120, 168, 240, 336 hrs and 504 hrs (i.e. Prior to Infusion of Cycle 5)

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The secondary objective is to assess the PK profile of pemetrexed + cisplatin + cixutumumab arm only.

End point values	Pemetrexed + Cisplatin + Cixutumumab			
Subject group type	Reporting group			
Number of subjects analysed	27 <sup>[24]</sup>			
Units: ug*hr/mL				
geometric mean (geometric coefficient of variation)	79700 ( $\pm$ 30)			

Notes:

[24] - Participants who were randomized to the cixutumumab arm and had evaluable PK data

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Entire Study

Adverse event reporting additional description:

I5A-MC-JAEM

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.1
--------------------	------

### Reporting groups

Reporting group title	Pemetrexed + Cisplatin + Cixutumumab
-----------------------	--------------------------------------

Reporting group description: -

Reporting group title	Pemetrexed + Cisplatin
-----------------------	------------------------

Reporting group description: -

Serious adverse events	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin	
Total subjects affected by serious adverse events			
subjects affected / exposed	49 / 85 (57.65%)	31 / 81 (38.27%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
metastases to bone			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
tumour pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
embolism			
alternative dictionary used: MedDRA 14.1			



subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
extremity necrosis				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
haematoma				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
hypertension				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	2 / 85 (2.35%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	1 / 2	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
hypotension				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	2 / 85 (2.35%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	1 / 4	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
peripheral arterial occlusive disease				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
peripheral artery thrombosis				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		

venous thrombosis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 1 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
Surgical and medical procedures osteosynthesis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
General disorders and administration site conditions fatigue alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	7 / 85 (8.24%) 9 / 9 0 / 0	1 / 81 (1.23%) 1 / 1 0 / 0	
general physical health deterioration alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 1 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
malaise alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 1 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
mucosal inflammation alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 1 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
non-cardiac chest pain			

alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 85 (2.35%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pyrexia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 85 (2.35%)	2 / 81 (2.47%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
sudden death			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Immune system disorders			
hypersensitivity			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
acute respiratory failure			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	2 / 81 (2.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
dyspnoea			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 85 (2.35%)	3 / 81 (3.70%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
epistaxis			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
haemoptysis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 85 (3.53%)	2 / 81 (2.47%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
hypoxia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pleural effusion			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	2 / 81 (2.47%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary embolism			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
pulmonary haemorrhage			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	

pulmonary oedema alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
respiratory failure alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
Psychiatric disorders confusional state alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
Investigations blood bilirubin increased alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 85 (2.35%) 2 / 3 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
blood creatinine increased alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 1 / 1 0 / 0	1 / 81 (1.23%) 1 / 1 0 / 0	
neutrophil count decreased alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 1 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
platelet count decreased alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	3 / 85 (3.53%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	7 / 7	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
white blood cell count decreased			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 85 (2.35%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	7 / 7	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
atrial fibrillation			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
myocardial infarction			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pericarditis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
cerebral ischaemia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
ischaemic stroke			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)		
occurrences causally related to treatment / all	0 / 0	3 / 3		
deaths causally related to treatment / all	0 / 0	1 / 1		
nervous system disorder				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
peripheral motor neuropathy				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
peripheral sensory neuropathy				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	2 / 2	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
seizure				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)		
occurrences causally related to treatment / all	0 / 1	0 / 0		
deaths causally related to treatment / all	0 / 0	0 / 0		
spinal cord compression				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)		
occurrences causally related to treatment / all	0 / 0	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		
syncope				
alternative dictionary used: MedDRA 14.1				
subjects affected / exposed	1 / 85 (1.18%)	1 / 81 (1.23%)		
occurrences causally related to treatment / all	0 / 1	0 / 1		
deaths causally related to treatment / all	0 / 0	0 / 0		

transient ischaemic attack alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
Blood and lymphatic system disorders			
anaemia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	6 / 85 (7.06%) 8 / 18 0 / 0	1 / 81 (1.23%) 0 / 1 0 / 0	
febrile neutropenia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	3 / 85 (3.53%) 3 / 3 1 / 1	5 / 81 (6.17%) 5 / 5 0 / 0	
leukopenia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 85 (0.00%) 0 / 0 0 / 0	1 / 81 (1.23%) 1 / 1 0 / 0	
neutropenia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	4 / 85 (4.71%) 4 / 4 2 / 2	2 / 81 (2.47%) 3 / 3 1 / 1	
pancytopenia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 85 (2.35%) 7 / 7 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
thrombocytopenia alternative dictionary used: MedDRA 14.1			



subjects affected / exposed	1 / 85 (1.18%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	3 / 3	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
vertigo			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 85 (2.35%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
vestibular disorder			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
blindness			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
abdominal pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
colitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
constipation			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
diarrhoea			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 85 (3.53%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
haemorrhoidal haemorrhage			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
inguinal hernia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
lower gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
nausea			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	5 / 85 (5.88%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	3 / 5	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
oesophagitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

stomatitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 85 (2.35%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
upper gastrointestinal haemorrhage			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 85 (2.35%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
vomiting			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	7 / 85 (8.24%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	8 / 9	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
cholecystitis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
acute kidney injury			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	5 / 85 (5.88%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	4 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
renal failure			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	2 / 85 (2.35%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Musculoskeletal and connective tissue disorders			

arthralgia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
bone pain			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
compartment syndrome			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
muscular weakness			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
rhabdomyolysis			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
dengue fever			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
device related infection			
alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
empyema			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
lobar pneumonia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
lung abscess			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
lung infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	0 / 85 (0.00%)	3 / 81 (3.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
mucosal infection			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
pneumonia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	3 / 85 (3.53%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	2 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

pneumonia klebsiella alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
pneumonia pneumococcal alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
postoperative abscess alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 85 (0.00%) 0 / 0 0 / 0	1 / 81 (1.23%) 0 / 1 0 / 0	
sepsis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	2 / 85 (2.35%) 2 / 2 1 / 1	1 / 81 (1.23%) 1 / 1 1 / 1	
septic shock alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 2 0 / 1	4 / 81 (4.94%) 2 / 7 1 / 3	
streptococcal bacteraemia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 85 (1.18%) 0 / 1 0 / 0	0 / 81 (0.00%) 0 / 0 0 / 0	
Metabolism and nutrition disorders decreased appetite alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	4 / 85 (4.71%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	4 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
dehydration			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	4 / 85 (4.71%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	5 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyperkalaemia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyperuricaemia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hypoalbuminaemia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hypocalcaemia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	0 / 81 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
hyponatraemia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	1 / 85 (1.18%)	1 / 81 (1.23%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Pemetrexed + Cisplatin + Cixutumumab	Pemetrexed + Cisplatin	
Total subjects affected by non-serious adverse events subjects affected / exposed	83 / 85 (97.65%)	79 / 81 (97.53%)	
Vascular disorders hypotension alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	8 / 85 (9.41%)  8	1 / 81 (1.23%)  1	
General disorders and administration site conditions asthenia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)  chest pain alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)  fatigue alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)  influenza like illness alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)  mucosal inflammation alternative dictionary used: MedDRA 14.1	10 / 85 (11.76%) 12  2 / 85 (2.35%) 3  36 / 85 (42.35%) 82  1 / 85 (1.18%) 1	9 / 81 (11.11%) 30  5 / 81 (6.17%) 10  33 / 81 (40.74%) 63  6 / 81 (7.41%) 7	



<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>non-cardiac chest pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>oedema peripheral</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>pyrexia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>12 / 85 (14.12%)</p> <p>18</p> <p>3 / 85 (3.53%)</p> <p>4</p> <p>7 / 85 (8.24%)</p> <p>7</p> <p>5 / 85 (5.88%)</p> <p>5</p>	<p>3 / 81 (3.70%)</p> <p>3</p> <p>6 / 81 (7.41%)</p> <p>6</p> <p>13 / 81 (16.05%)</p> <p>19</p> <p>10 / 81 (12.35%)</p> <p>14</p>	
<p>Respiratory, thoracic and mediastinal disorders</p> <p>cough</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dyspnoea</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>epistaxis</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>productive cough</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>13 / 85 (15.29%)</p> <p>21</p> <p>14 / 85 (16.47%)</p> <p>21</p> <p>7 / 85 (8.24%)</p> <p>11</p> <p>1 / 85 (1.18%)</p> <p>1</p>	<p>16 / 81 (19.75%)</p> <p>20</p> <p>16 / 81 (19.75%)</p> <p>26</p> <p>0 / 81 (0.00%)</p> <p>0</p> <p>5 / 81 (6.17%)</p> <p>14</p>	
<p>Psychiatric disorders</p> <p>anxiety</p> <p>alternative dictionary used: MedDRA 14.1</p>			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>depression</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>insomnia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 85 (3.53%)</p> <p>3</p> <p>5 / 85 (5.88%)</p> <p>5</p> <p>5 / 85 (5.88%)</p> <p>5</p>	<p>5 / 81 (6.17%)</p> <p>6</p> <p>4 / 81 (4.94%)</p> <p>4</p> <p>7 / 81 (8.64%)</p> <p>10</p>	
<p>Investigations</p> <p>alanine aminotransferase increased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>aspartate aminotransferase increased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>blood creatinine increased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>neutrophil count decreased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>platelet count decreased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>weight decreased</p> <p>alternative dictionary used: MedDRA 14.1</p>	<p>8 / 85 (9.41%)</p> <p>11</p> <p>4 / 85 (4.71%)</p> <p>4</p> <p>12 / 85 (14.12%)</p> <p>18</p> <p>9 / 85 (10.59%)</p> <p>24</p> <p>6 / 85 (7.06%)</p> <p>6</p>	<p>4 / 81 (4.94%)</p> <p>6</p> <p>5 / 81 (6.17%)</p> <p>7</p> <p>16 / 81 (19.75%)</p> <p>20</p> <p>6 / 81 (7.41%)</p> <p>10</p> <p>9 / 81 (11.11%)</p> <p>14</p>	

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>white blood cell count decreased</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>17 / 85 (20.00%)</p> <p>28</p> <p>5 / 85 (5.88%)</p> <p>10</p>	<p>11 / 81 (13.58%)</p> <p>13</p> <p>4 / 81 (4.94%)</p> <p>6</p>	
<p>Nervous system disorders</p> <p>dizziness</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>dysgeusia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>paraesthesia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>11 / 85 (12.94%)</p> <p>13</p> <p>7 / 85 (8.24%)</p> <p>9</p> <p>2 / 85 (2.35%)</p> <p>3</p>	<p>5 / 81 (6.17%)</p> <p>7</p> <p>8 / 81 (9.88%)</p> <p>10</p> <p>5 / 81 (6.17%)</p> <p>5</p>	
<p>Blood and lymphatic system disorders</p> <p>anaemia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>leukopenia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>neutropenia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>thrombocytopenia</p> <p>alternative dictionary used: MedDRA 14.1</p>	<p>33 / 85 (38.82%)</p> <p>103</p> <p>6 / 85 (7.06%)</p> <p>12</p> <p>12 / 85 (14.12%)</p> <p>29</p>	<p>36 / 81 (44.44%)</p> <p>98</p> <p>5 / 81 (6.17%)</p> <p>27</p> <p>17 / 81 (20.99%)</p> <p>35</p>	

subjects affected / exposed occurrences (all)	8 / 85 (9.41%) 31	5 / 81 (6.17%) 9	
Ear and labyrinth disorders vertigo alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	9 / 85 (10.59%) 11	4 / 81 (4.94%) 4	
Eye disorders lacrimation increased alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	8 / 85 (9.41%) 8	7 / 81 (8.64%) 10	
Gastrointestinal disorders abdominal pain alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	4 / 85 (4.71%) 6	11 / 81 (13.58%) 15	
constipation alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	27 / 85 (31.76%) 39	19 / 81 (23.46%) 28	
diarrhoea alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	19 / 85 (22.35%) 29	16 / 81 (19.75%) 21	
dyspepsia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	5 / 85 (5.88%) 5	3 / 81 (3.70%) 4	
dysphagia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	5 / 85 (5.88%) 5	1 / 81 (1.23%) 1	
nausea alternative dictionary used: MedDRA 14.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>45 / 85 (52.94%)</p> <p>74</p> <p>41 / 81 (50.62%)</p> <p>101</p>			
<p>stomatitis</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>14 / 85 (16.47%)</p> <p>24</p> <p>6 / 81 (7.41%)</p> <p>8</p>			
<p>vomiting</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>29 / 85 (34.12%)</p> <p>41</p> <p>28 / 81 (34.57%)</p> <p>55</p>			
<p>Skin and subcutaneous tissue disorders</p> <p>alopecia</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>7 / 85 (8.24%)</p> <p>8</p> <p>3 / 81 (3.70%)</p> <p>3</p>			
<p>rash</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>7 / 85 (8.24%)</p> <p>7</p> <p>4 / 81 (4.94%)</p> <p>5</p>			
<p>Musculoskeletal and connective tissue disorders</p> <p>back pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>9 / 85 (10.59%)</p> <p>10</p> <p>10 / 81 (12.35%)</p> <p>13</p>			
<p>bone pain</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>2 / 85 (2.35%)</p> <p>3</p> <p>5 / 81 (6.17%)</p> <p>5</p>			
<p>pain in extremity</p> <p>alternative dictionary used: MedDRA 14.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>5 / 85 (5.88%)</p> <p>6</p> <p>2 / 81 (2.47%)</p> <p>2</p>			
<p>Infections and infestations</p>			

conjunctivitis alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	3 / 85 (3.53%) 5	5 / 81 (6.17%) 6	
upper respiratory tract infection alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	2 / 85 (2.35%) 2	6 / 81 (7.41%) 7	
Metabolism and nutrition disorders			
decreased appetite alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	24 / 85 (28.24%) 36	27 / 81 (33.33%) 32	
dehydration alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	10 / 85 (11.76%) 13	6 / 81 (7.41%) 8	
hyperglycaemia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	43 / 85 (50.59%) 156	16 / 81 (19.75%) 45	
hyperkalaemia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	5 / 85 (5.88%) 8	2 / 81 (2.47%) 3	
hypocalcaemia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	5 / 85 (5.88%) 7	1 / 81 (1.23%) 1	
hypokalaemia alternative dictionary used: MedDRA 14.1 subjects affected / exposed occurrences (all)	6 / 85 (7.06%) 7	4 / 81 (4.94%) 4	
hypomagnesaemia alternative dictionary used: MedDRA 14.1			

subjects affected / exposed	9 / 85 (10.59%)	6 / 81 (7.41%)	
occurrences (all)	13	6	
hyponatraemia			
alternative dictionary used: MedDRA 14.1			
subjects affected / exposed	5 / 85 (5.88%)	4 / 81 (4.94%)	
occurrences (all)	5	5	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 April 2011	<p>The changes made to the protocol were as follows:</p> <ul style="list-style-type: none"><li>clarification of inclusion and exclusion criteria</li><li>clarification of the discontinuation of patients</li><li>clarification of treatment administration</li><li>clarification of hyperglycemia assessments</li><li>clarification of the definition of time to progression disease</li><li>addition of an interim analysis for safety, after 50 patients complete 2 cycles</li><li>additional hematology/chemistry assessments during induction (Cycles 1-4) to comply with cisplatin label</li><li>specification that physical exams will include neurologic assessments to comply with the cisplatin label</li><li>addition of sampling windows to pharmacokinetics sampling table</li></ul>
22 November 2011	<p>The changes to the protocol were as follows:</p> <ul style="list-style-type: none"><li>inclusion of an independent data assessment committee (IDAC) and clarification of the roles of data assessment committee and IDAC</li><li>modification of glucose inclusion criteria and criteria for starting and stopping daily testing</li><li>adding an option to extend cisplatin therapy through Cycle 6 for qualifying participants (after Sponsor consultation) and corresponding addition of weekly hematology and -chemistry for these participants</li><li>modification of chemistry sampling in Cycle 1 for all participants -update of compound background information to be consistent with the most recent IB</li><li>removal of requirement for full local chemistry panel at each central chemistry time point</li><li>clarification of use and interpretation of central versus local laboratory chemistry data</li><li>addition of fasting requirements (minimum of 4 hours) prior each chemistry or glucose assessment</li></ul>
09 March 2012	<p>The changes to the protocol were as follows:</p> <p>The level of acceptable efficacy has now been reestimated to be at least 7.16 months.</p>



11 April 2012	<p>The changes to the protocol were as follows:</p> <p>The protocol has been updated to include drug product at a concentration of 15 mg/mL (750 mg/50 mL).</p>
19 February 2013	<p>The changes to the protocol were as follows:</p> <p>Addition of the extension period</p>

Notes:

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported